Back to ALCView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
3 competitors in Macular Edema
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA12/11/2007
Nevanac
Nevanac is indicated for: prevention and treatment of postoperative pain and inflammation associated with cataract surgery; reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Ofloxacin otic solutionPhase 3
Acute Otitis Media
Difluprednate 0.05% ophthalmic emulsionPhase 3
Endogenous Anterior Uveitis
Olopatadine Hydrochloride Ophthalmic Solution, 0.2%Phase 3
Allergic Conjunctivitis
AL-4943A ophthalmic solutionPhase 3
Allergic Conjunctivitis
Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solutionPhase 3
Glaucoma, Open-angle
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts